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INTRODUCTION 
In 2050 the number of people aged ≥60 years will 
increase  by  1.25 billion [1] with  an  estimate of  115.4  
million of persons with dementia [2]. Alzheimer’s 
disease (AD) is the cause of 60–70% of dementia, 
affecting 48 million of people worldwide [3], causing 
severe clinical, social, and economic problems [1].  
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ABSTRACT 
Cognitive and physical activity treatments (CT and PT) are two non-pharmacological approaches frequently 
used in patients with Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD). The aim of this study was 
to compare CT and PT in these diseases. Eighty-seven patients were randomly assigned to CT (n=30), PT (n=27) 
or control group (CTRL; n=30) for 6 months. The global cognitive function was measured by Mini Mental State 
Examination (MMSE). Specific neuropsychological tests explored attention, memory, executive functions, 
behavioral disorders. Cardiovascular risk factors (CVD) were collected. All measures were performed before 
(T0), after treatments (T1), and at three-months follow-up (T2). MMSE did not change from T0 to T1 and T2 in 
patients assigned to PT and CT, while CTRL patients showed a decline MCI: -11.8%, AD: -16.2%). Between group 
differences (MCI vs AD) were not found at T1 and T2. Significant worsening was found for CTRL in MCI (T0- T1: 
P=.039; T0-T2: P<.001) and AD (T0-T1: P<.001; T0-T2: P<.001), and amelioration was found for CT in AD (T0-T2: 
P<.001). Attention, executive functions and behavioral disorders were unaffected by either PT or CT. Memory 
was increased in patients with MCI assigned to PT (+6.9%) and CT (+8.5%).. CVD were ameliorated in the PT 
group. CTRL patients of both groups, revealed significant decline in all functions and no between groups 
differences were detected. PT appear to ameliorate CVD. Although between groups differences were not 
found, results suggest a major retention in MCI compared with AD, suggesting that the latter might benefit 
better of constant rather than periodic treatments. This study confirms the positive effects of CT and PT in 
mitigating the cognitive decline in MCI and AD patients, and it is the first to demonstrate their similar 
effectiveness on maintaining cognitive function. 
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AD is characterized by intraneuronal fibrillary tangles 
and extracellular deposit of amyloid plaques (Aβ) coup-
led with reactive microgliosis, loss of neurons and 
synapses in the cortex [4]. Deposits of Aβ can lead to 
cortical dysfunctions resulting in many cognitive 
impairments such as memory and intellectual disabili-
ties, causing a decline in activities of daily living and 
interfering with quality of life [5]. Although current 
pharmacological treatments may improve symptoms, 
there are no disease-modifying strategies for AD and 
new non-pharmacological interventions are needed [6].  
 
Individuals with Mild Cognitive Impairment (MCI), 
which show cognitive changes greater than expected for 
an individual’s age and education level but do not 
interfere with daily-life activities, have increased risk of 
dementia. The estimated global prevalence of MCI is 
9.6–21.6% [7, 8]. Pharmacological treatments for MCI 
have modest to no effect, and new therapeutic appro-
aches are needed in this condition [9]. Cognitive 
stimulation is the most recommended non-pharma-
cological approach for cognitive symptoms in MCI and 
mild-to-moderate dementia. Despite these promising 
results, the evidence for cognitive training is still 
preliminary [10].  
 
Physical activity treatment (PT) is another non-
pharmacological treatment with some efficacy in 
dementia [11, 12]. The potential of PT to attenuate the 
cognitive decline in healthy elderly is clear [13], but the 
effects of PT on cognitive decline is less consistent 
because of methodological limits, such as different 
exercise interventions and small sample size. A sys-
tematic review [14] showed that aerobic and resistance 
PT had some positive effects on global cognition, 
executive functions, attention and delayed recall in 
MCI and no cognitive effects in AD. Other studies 
indicated that PT improve global cognitive ability and 
memory in MCI [15]. PT was reported to delay the 
cognitive decline in persons at risk of or who have AD 
[12].  
 
Unfortunately, to date these data are still unclear due to 
the heterogeneity between studies and outcomes [11]. 
Therefore, further research with additional and more 
specific neuropsychological measurements are needed. 
The aim of this study was to compare the effects of 
cognitive treatment (CT) and PT in older people with 
AD and in subjects with MCI. Our hypothesis was that 
both CT and PT would attenuate the progression of 
cognitive deterioration in AD and MCI, with similar 
results in primary outcome measure, but different 
effects in the secondary outcome measures. Specifical-
ly, we expected amelioration in the memory domain in 
CT group, while PT group would exhibit improvements 
in physical function and attention.  
RESULTS 
 
Demographic and clinical data 
 
The flow diagram of the study with the specific 
numbers of participants is reported in Figure 1. The 
sample was composed of 27 MCI (11 males/16 females) 
and 60 patients with AD (21 males/39 females). They 
were randomized to the CT group (n = 30), PT group (n 
= 27) or the CTRL group (n = 30). Age, education, 
MMSE and POMA were not statistically different 
between the three groups of AD and the three groups of 
MCI at baseline. Patients’ demographic and clinical 
characteristics are reported in Table 1. Primary and 
secondary outcomes measures did not significantly 
differ between the three groups at baseline (T0). 
 
Primary outcomes 
 
Significant effects of the factors Time (F2,162= 59.327; 
P<.001), Treatment (F2,81= 4.584; P=.013) and Group 
(F1,81= 86.707; P<.001) and Time X Treatment 
interaction (F4,162= 15.328; P<.001) on MMSE were 
found.  
 
Post-hoc tests revealed no difference between the three 
treatments’ groups at T1 and T2 both in patients with 
MCI and AD. However, in MCI amelioration in CTRL 
were found (T0- T1: P=.039; T0-T2: P<.001). In AD 
worsening in CTRL (T0-T1: P<.001; T0-T2: P<.001), 
and amelioration in CT (T0-T2: P<.001) were seen (see 
Figure 2). 
 
Secondary cognitive and behavioral outcomes in 
MCI and AD 
 
Significant effects of the factors Time (F2,162= 11.444; 
P<.001), Treatment (F2,81= 4.077; P=.020) and Group 
(F1,81= 39.840; P<.001) and Time x Treatment (F4,162= 
10.887; P<.001) and Time x Group (F2,162= 5.277; 
P=.006) interactions on FAB. Post-hoc comparisons 
revealed no significant results in MCI, but in AD a 
significant difference between CTRL and CT in T2 
(P=.041). Moreover, in AD a worsening of CTRL in 
time (T0-T1: P<.000; T0-T2: P<.000) was found. 
 
Effects of the factors Time (F2,162= 29.885; P<.001) and 
Group (F1,81= 38.598; P<.001) and the Time X 
Treatment (F4,162= 5.032; P<.001) and Time X 
Treatment X Group (F4,162= 2.575; P=.039) interactions 
were found on IADL. Post-hoc did not reveal any 
difference at T1 and T2 between the three treatments’ 
groups in patients with MCI and in patients with AD. 
We found a worsening of CTRL between T0 and T2 
(P<.001) in MCI, and differences from T0 to T2 in CT 
(P<.001) and CTRL (P<.001) in AD.  
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Significant effects of Time (F2,162= 18.425; P<.001), 
Treatment (F2,81= 18.204; P<.001), Group (F1,81= 
15.255; P<.001) and Time X Treatment (F4,162= 21.339; 
P<.001) and Treatment X Group (F2,81= 6.605; P=.002) 
interactions on NPI. Post-hoc showed difference 
between groups at T1 (PT vs. CTRL: P<.001; CT vs. 
CTRL: P<.001) and at T2 (PT vs. CTRL: P<.001; CT 
vs. CTRL: P<.001) in AD. Moreover, we found changes 
from T0 to T2 in CTRL (P<.001) in MCI and  
worsening of CTRL across time (T0-T1: P=.001; T0-
T2: P<.001) in AD (Table 2). 
 
Secondary cognitive outcomes specific for MCI  
 
Significant effects of Time (F2,48= 7.33; P=.001), 
Treatment (F2,24= 5.286; P=.012) and Time X 
Treatment interaction (F4,48= 5.715; P<.001) on TMT-
A. Post-hoc showed differences at T1 (PT vs. CTRL: 
P=.014; CT vs. CTRL: P=.040), and T2 (PT vs. CTRL:  
P=.001; CT vs. CTRL: P<.001). A worsening of CTRL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
across time was found (T0-T1: P=.006; T0-T2: 
P<.001). 
 
In TMT-B, effects of Time (F2,48= 12.46; P<.001), 
Treatment (F2,24= 8.46; P=.001) and Time x Treatment 
(F4,48= 11.93; P<.001) interaction were found. Post-hoc 
showed differences at T1 between PT and CTRL 
(P=.002), and CT and CTRL (P<.001), both confirmed 
at T2 (P<.001). A worsening of CTRL was found 
between T0 and T1 (P<.001) and T0 and T2 (P<.001). 
 
Effects of Time (F2,48= 16.88; P<.001), Treatment 
(F2,24= 3.434; P=.048) and Time X Treatment 
interaction (F4,48= 10.06; P<.001) on RBMT were 
found. Post-hoc tests showed differences at T1 (PT vs. 
CTRL: P=.022; CT vs. CTRL: P=.006) and T2 (PT vs. 
CTRL: P=.017; CT vs. CTRL: P=.028) and changes 
from T0 to T1 in all treatments’ groups (PT: P=.019; 
CT: P<.001; CTRL: P=.006), and from T0 to T2 in 
CTRL (P<.001) (see Table 3). 
Figure 1. Flow diagram of the randomized controlled trial. Abbreviations: MCI: Mild Cognitive Impairment; AD: Alzheimer’s 
Disease; M: Male; F: Female. 
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Secondary cognitive outcomes specific for AD 
 
Effects of Time (F2,114= 30.81; P<.001) and Time X 
Treatment interaction (F4,114= 23.93; P<.001) were 
found on DCT. Within-group comparisons showed 
changes from T0 to T1 in PT (P=.002) and CTRL 
(P<.001), and from T0 and T2 in CTRL (P<.001). 
 
Effects of the  factors Time  (F2,114= 49.05; P<.001) and  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the Time X Treatment interaction (F4,114= 15.48; 
P<.001) were found on ADAS-Cog, with changes in PT 
(T0-T1: P=.037; T0-T2: P=.005) and in CTRL (T0 to 
T1: P<.001; T0 to T2: P<.001). 
 
Post-hoc did not show any difference at T1 and T2 
between the three treatments’ groups both in DCT and 
in ADAS-Cog (Table 4). 
Table 1. Demographic data. 
   CT (30) PT (27) CTRL (30) 
 
  AD (19) MCI (11) AD (20) MCI (7) AD (21) MCI (9) 
Numbers 7♂/12♀ 5♂/6♀ 6♂/14♀ 4♂/3♀ 8♂/13♀ 2♂/7♀ 
Age (years) 79±7 76±5 79±9 75±5 80±7 79±3 
Education (years) 8±5 9±4 7±4 10±4 7±3 8±4 
MMSE (0-30) 19.6±4.3 26.4±1.4 17.8±5.7 27±2.2 18.7±2.3 25.7±1.8 
POMA (0-28) 22.9±3.7 25.4±2.3 22.7±2.9 26.1±2.4 23.8±3.2 24.4±3.5 
CDR (0-3) 9 CDR=1 11 CDR=0.5 9 CDR=1 7 CDR=0.5 11 CDR=1 9 CDR=0.5 
   10 CDR=2   11 CDR=2   10 CDR=2   
Height (m) 1.65 1.66 1.62 1.67 1.65 1.62 
Weight (kg) 65.4 73.9 67.4 79.9 67.1 73.0 
Resting HR (bpm)  40 59 66 59 74 65 
Pharmacological treatment             
  
Cholinesterase 
Inhibitors  9 2 9 1 9 0 
  Antipsychotics 4 0 5 0 4 0 
  Antidepressants 8 4 11 3 13 1 
  Benzodiazepines  2 0 1 0 6 0 
Comorbidity             
  Hypertension 13 8 8 6 11 4 
  
Cardiovascular 
diseases 10 6 5 2 8 3 
  Diabetes 1 3 1 3 1 3 
  Arthrosis 1 1 4 0 1 0 
Data are given as mean ± standard deviation. Abbreviations: CT: Cognitive Treatment group; PT: Physical Treatment 
group; CTRL: Control Group; MMSE: Mini Mental State Examination; POMA: Performance Oriented Mobility 
Assessment; CDR: Clinical Dementia Rating Scale; Resting HR: Heart Rate at rest.  
*= Statistically significant at p ≤ 0.05 
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Figure 2. Primary outcome in MCI and AD. Abbreviations: MCI: Mild Cognitive Impairment; AD: Alzheimer’s Disease; PT: Physical 
Treatment group; CT: Cognitive Treatment group; CTRL: Control Group. Within-group comparison significant results (p ≤ 0.05): ▲ T0-T1; 
■ T0-T2. Between-groups significant results (p ≤ 0.05): ★ T1 PT vs T1 CTRL; ✦ T1 CT vs T1 CTRL; ☆ T2 PT vs T2 CTRL; ✧ T2 CT vs T2 CTRL. 
 
Table 2. Secondary cognitive and behavioral outcomes in MCI and AD. 
   Treatment Groups T0 T1 T2 
Within-group 
comparison 
(Time) 
Between-groups 
comparison 
(Treatment) 
         
FAB  
(0-18) 
PT MCI AD 
12.9±2.5 
8.9±2.4 
13.4±3.6 
9.9±2.4 
12.7±3.5 
8.5±2.8   
CT MCI AD 
11.7±2 
8.6±1.9 
12.8±2.7 
9.1±2.3 
12.7±3.1 
7.7±2.9  AD: ✧ 
CTRL MCI AD 
11.7±3 
10.3±2.6 
10.2±3.6 
7.3±2.9 
9.8±3.4 
5.3±2.8 
 
▲ ■   
         
IADL  
(0-100%) 
PT MCI AD 
88.2±23.6 
56.2±35.1 
86.4±22.1 
50.5±32.9 
81.8±21.2 
39.2±31.2   
CT MCI AD 
84.1±19.8 
58.5±28.8 
89.5±18.8 
54.1±29.8 
86.1±19.6 
38.2±26.6 
■ 
  
CTRL MCI AD 
84.4±25.9 
48.9±23.4 
73.1±34.3 
34±25.5 
56.4±33.8 
21.1±18.3 
■ 
■   
        
NPI  
(1-144) 
PT MCI AD 
11.7±9.1 
12.7±8.7 
7±4.2 
9.5±6.8 
9.9±5.7 
11±5.4   
CT 
MCI 
AD 10.7±7.3 
13.6±8.9 
6±4.9 
9.6±7.1 
11.4±7.9 
13.7±10.4  AD: ★✦☆✧ 
CTRL MCI AD 
6.2±2.9 
16.1±8.8 
13.8±11.2 
29.7±9.7 
20.9±17.9 
40±11.3 
■ 
▲ ■   
Data are given as mean ± standard deviation. Abbreviations: PT: Physical Treatment group; CT: Cognitive Treatment 
 group; CTRL: Control group; FAB: Frontal Assessment Battery; IADL: Instrumental Activity of Daily Living; NPI: 
Neuropsychiatric Inventory. T0: Pre-Treatment assessment; T1: Post-Treatment assessment; T2: Follow-p assessment. 
Within-group (Time) comparison significant results (p ≤ 0.05): ▲ T0-T1; ■ T0-T2. 
Between-groups (Treatment) significant results (p ≤ 0.05): ★ T1 PT vs T1 CTRL; ✦ T1 CT vs T1 CTRL; ☆ T2 PT vs T2 CTRL; 
✧ T2 CT vs T2 CTRL. 
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Table 3. Secondary cognitive outcomes specific for MCI. 
  Treatment  T0 T1 T2  
Between-groups 
comparison 
(Treatment) 
        
TMT-A (sec.) 
PT 95.6±15 82±12.2 94±17.3 
 
★✦☆✧  CT 87.6±28.2 97±47.1 97.1±36.3  
CTRL 111.8±64.9 149.1±68.8 180.7±62.6 ▲ ■  
       
TMT-B (sec.) 
PT 209.1±48.7 190.1±30.6 195.7±39.8 
 
★✦☆✧  CT 193.9±56.5 173.1±53.3 215.2±76.5  
CTRL 233±67.2 297.3±71 331.4±54.7 ▲ ■  
       
RBMT (0-212) 
PT 79±29.1 93.6±35.6 81.7±37 ▲ 
★✦☆✧  CT 77±30.3 95.1±31.4 74.5±36.2 ▲ 
CTRL 66.2±22.3 51.6±25.4 38.3±21.1 ▲ ■  
Data are given ad mean ± standard deviation. Abbreviations: PT: Physical Treatment group; CT: Cognitive Treatment 
group; CTRL: Control group. TMT: Trail Making Test; RBMT: Rivermead Behavioral Memory Test; FAB: Frontal 
Assessment Battery; IADL: Instrumental Activity of Daily Living; NPI: Neuropsychiatric Inventory. T0: Pre-Treatment 
assessment; T1: Post-Treatment assessment; T2: Follow-p assessment. 
Within-group comparison significant results (p ≤ 0.05): ▲ T0-T1; ■ T0-T2. 
Between-groups significant results (p ≤ 0.05): ★ T1 PT vs T1 CTRL; ✦ T1 CT vs T1 CTRL; ☆ T2 PT vs T2 CTRL; ✧ T2 CT vs T2 
CTRL 
 
Table 4. Secondary cognitive outcomes specific for AD. 
   Treatment T0 T1 T2 
Within- group 
comparison 
(Time) 
Between- groups 
comparison 
(Treatment) 
        
DCT (0-60) 
PT 25.5±11.4 29.5±10.8 25.0±10.6 ▲  
 CT 23.9±9.3 25.5±7.8 22.9±10.2  
CTRL 33.3±10.8 25.3±12.2 20.0±11.4 ▲ ■  
       
ADAS-Cog  
(0-70) 
PT 33.3±17.9 30.1±16.1 37.2±17.9 ▲ ■  
 CT 27.1±7.6 25.5±7.5 30.1±9.2  
CTRL 25.9±9.5 34±9.3 38.7±10.8 ▲ ■  
Data are given as mean ± standard deviation. Abbreviations: PT: Physical Treatment group; CT: Cognitive Treatment group; 
CTRL: Control group; DCT: Digit Cancellation Test, ADAS-Cog: Cognitive section of the Alzheimer’s Disease Assessment Scale; 
FAB: Frontal Assessment Battery; IADL: Instrumental Activity of Daily Living; NPI: Neuropsychiatric Inventory. T0: Pre-
Treatment assessment; T1: Post-Treatment assessment; T2: Follow-p assessment. 
Within-group comparison significant results (p ≤ 0.05): ▲ T0-T1; ■ T0-T2. 
Between-groups significant results (p ≤ 0.05): ★ T1 PT vs T1 CTRL; ✦ T1 CT vs T1 CTRL; ☆ T2 PT vs T2 CTRL; ✧ T2 CT vs T2 
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Exercise capacity and cardiovascular risk factors in 
MCI and AD 
 
Effects of Time (F2,162= 5.526; P=.004) and Time X 
Treatment (F4,162= 9.673; P=.040) and Time X 
Treatment X Group (F4,162= 2.560; P=.040) interactions 
on BMI were seen. No between-groups differences were 
found in the post-hoc analysis. However, they indicated 
anBMI increased for CTRL in MCI (T0-T2: P=.008) 
and changes from T0 to T1 (P=.011) for PT in AD group. 
 
Effects of the factors Time (F2,162= 18.663, P<.001), 
Treatment (F2,81= 5.322, P=.006) and Group (F1,81= 
10.806; P=.001) and Time X Treatment interaction 
(F4,162= 15.487; P<.001) were found on 6MWT. Post-
hoc analysis did not show any difference between the 
three treatments’ groups both in AD and in MCI. We 
showed changes in CTRL both in MCI and in AD from 
T0 to T2 (P=.004 and P<.001 respectively) and from T0 
to T1 for CTRL in AD (P<.001). 
 
Effects of the factors Time (F2,162= 22.53, P<.001), 
Treatment (F2,81= 13.10, P<.001) and the Time X 
Treatment interaction (F4,162= 26.76; P<.001) on systolic 
blood pressure were found. Post-hoc showed differences 
in MCI at T1 (PT vs. CTRL: P=.008) and in AD at T1 
(PT vs. CTRL: P=.001) and at T2 (PT vs. CTRL: P=.025, 
CT vs. CTRL: P=.016). Moreover, changes in PT and in 
CTRL were found in MCI (PT, T0-T1: P=.003; CTRL, 
T0-T1: P=.041, T0-T2: P=.001) and in AD (PT, T0-T1: 
P<.001; CTRL, T0-T1: P=.002, T0-T2: P<.001). 
 
Effects of the factors Time (F2,162= 12.41, P<.001), 
Treatment (F4,81= 4.63, P=.012) and the Time X 
Treatment (F4,162= 24.70, P<.001) and Time X 
Treatment X Group (F4,162= 2.69, P=.033) interaction on 
diastolic blood pressure were seen. Post-hoc showed 
differences between PT and CTRL at T1 both in MCI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and in AD (P=.002, P=.002). A worsening in CTRL 
(T0-T1: P<.001, P=.001; T0-T2: P<.001, P<.001) were 
found both in MCI and AD. An improvement was found 
for PT in AD (T0-T1: P<.001). 
 
Effects of Time (F2,162= 9.520; P<.001), Group (F1,81= 
14.985; P<.001) and Time X Treatment (F4,162= 12.581; 
P<.001) and Time X Group (F2,162= 3.978; P=.020) 
interactions were found in glucose blood level. No 
between-groups differences were shown in the post-hoc 
analysis, but an improvement was found for PT in MCI 
and AD from T0 to T1 (P<.001, P=.010). 
 
Effects of the factors Treatment (F2,81= 3.261; P=.043) 
and Group (F1,81= 16.672; P<.001) on total cholesterol, 
with no between-groups changes in the post-hoc 
analysis, but significant difference for CTRL in AD 
between T0 and T2 (P=.032) were found. 
 
For HDL, only the Time X Treatment (F4,162= 6.412, 
P<.001) and Time X Treatment X Group (F4,162= 7.526, 
P<.001) interactions were significant, with neither betwe-
en nor within-groups effects in the post-hoc analysis. 
 
Effect of Time (F2,162= 5.428, P=.005), Treatment 
(F1,81= 36.252, P<.001) and Time X Treatment (F4,162= 
2.966; P=.021), Time X Group (F2,162= 16.230; P<.001) 
and Time X Treatment X Group (F4,162= 6.955; P<.001) 
interactions on LDL were found. Post-hoc analysis 
showed no between-groups differences, but changes in 
PT both in MCI and in AD (T0-T1: P=.015, P<.001). 
 
For triglycerides, an effect of Time (F2,162= 10.201; 
P<.001) and Time X Treatment interaction (F2,162= 
6.771; P<.001) were found. Post-hoc analysis did not 
find any difference between the three treatments’ 
groups, but a difference for PT in AD between T0 and 
T1 (P<.001; Table 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Exercise capacity and cardiovascular risk factors in MCI and AD. 
  Treatment Groups T0 T1 T2 
Within-group 
comparison 
(Time) 
Between-
groups 
comparison 
(Treatment) 
BMI (kg/m2) 
PT MCI AD 
28.5±4.8 
25.6±3.4 
27.1±4.4 
24.5±2.8 
27.1±4.4 
25.6±3.17 
 
▲ 
CT MCI AD 
26.2±5.1 
25.8±5.5 
25.8±5 
25.6±5.3 
26±5.1 
26.2±5.5 
 
CTRL MCI AD 
27±3.2 
26.9±3.1 
28±3.5 
27.4±3.3 
28.7±3.1 
27.6±3.4 ■          
6MWT (m) 
PT MCI AD 
391.9±57.1 
323.1±115.4 
447.9±73.8 
347.6±94.4 
398.3±69.8 
334.1±116.3  
CT MCI AD 
440.1±95.4 
336±109.2 
399.7±90.9 
318.2±106.3 
395.9±68.9 
317.3±105.5  
CTRL MCI AD 
352.8±55.4 
342.5±40.9 
314.6±44.4 
271±73.3 
285.4±29.3 
253.1±74.2 
■ 
▲■ 
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SYS (mmHg) 
PT MCI AD 
130.1±6.1 
129.2±5 
125.9±3 
124.4±4.2 
130±4.9 
129±4.6 
▲ 
▲ 
MCI: ★  
AD: ★☆✧ 
CT MCI AD 
130.6±3.6 
128.7±6.2 
130.2±4.1 
128.7±6.3 
131.2±3 
128.7±6.4  
CTRL MCI AD 
135.2±11.5 
132.3±6 
138.44±9.5 
134.8±5.4 
139.3±9.4 
136.2±5 
▲ ■ 
▲ ■ 
      
 
 
DIA (mmHg) 
PT MCI AD 
87.9±7.1 
87.7±3.6 
84.4±5.1 
84.6±2.4 
88.3±5.6 
87.6±2.6 
 
▲  
CT 
MCI 
AD 
88±3.7 
87.1±3.5 
87.1±5.1 
87.8±3.1 
87.4±4.2 
88±3.3 
 MCI: ★ 
AD: ★ 
CTRL MCI AD 
86.9±2.3 
86.6±2.1 
91.9±3.1 
89.2±1.2 
91.7±2.1 
89.4±1 
▲ ■ 
▲ ■          
GLUCOSE 
(mg/dL) 
PT MCI AD 
119.6±24.2 
99.3±8.6 
98.43±5 
91±10.4 
112.3±16.9 
95.6±9 
▲ 
▲ 
 CT MCI AD 
106±19.1 
98.2±12.6 
105.3±20.9 
97.9±13.2 
111.4±19 
97.6±13.1 
 
CTRL MCI AD 
103±12.8 
96.3±13.2 
107.7±9.6 
98.9±12.1 
109±9.5 
98.2±11 
 
        
TOTAL 
CHOLESTEROL 
(mg/dL) 
PT MCI AD 
167.7±16.9 
207.3±34.2 
135.7±9.5 
189±36.3 
161±11.3 
20.5±27.6   
 CT MCI AD 
174.9±28.2 
200.8±24.3 
177.5±37.5 
196.7±23.3 
171.2±23.1 
198.5±18.6 
 
CTRL MCI AD 
182.9±16.4 
196.4±28.2 
189.4±13.9 
206.8±29.9 
191.2±15.1 
250.6±154.9 
 
■ 
        
 PT MCI AD 
63±13 
50.2±9.7 
68.7±10.2 
55±12.2 
57.4±16.8 
52.1±11.9 
 
  
HDL (mg/dL) CT MCI AD 
58.8±21.4 
59.3±15.2 
57.8±15.7 
54±14.2 
52.8±10 
58.2±12.3 
 
  
 CTRL MCI AD 
57.6±9.3 
55.6±10.7 
53.6±11.5 
54.2±9.8 
63.3±8.1 
51.6±8.5 
 
  
        
 PT MCI AD 
90.1±14.1 
124.8±18.7 
105.9±14 
112.2±16.6 
89.7±16.3 
123±20.1 
▲ 
▲  
LDL (mg/dL) CT MCI AD 
94.4±12.3 
120.7±21 
100.7±12.7 
118.8±20.2 
98±13 
120.4±17.7   
 CTRL MCI AD 
90.8±6.4 
119.7±23.3 
100.1±5.4 
125.3±22.9 
102.3±4.7 
125.7±21.4   
        
 PT MCI AD 
125.4±11.7 
129.2±41 
111.6±16.4 
111.8±36.3 
129.7±18.7 
126.1±37.6 
 
▲  
TRIGLYCERIDES 
(mg/dL)  CT 
MCI 
AD 
115.55±12.6 
118.8±37.8 
115.6±10.5 
125.4±37.7 
119±12.5 
127.5±36.4 
 
  
 CTRL MCI AD 
114.2±18.3 
124.2±22.9 
118.1±17.6 
128.9±25.1 
123.3±14.3 
132±24.4   
Data are given as mean ± standard deviation. Abbreviations: PT: Physical Treatment group; CT: Cognitive Treatment 
group; CTRL: Control group. BMI: Body Mass Index; 6MWT: 6-Minute Walking Test; SYS: Systolic blood pressure; DIA: 
Diastolic blood pressure; HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein. T0: Pre-Treatment assessment; 
T1: Post-Treatment assessment; T2: Follow-p assessment. 
Within-group comparison significant results (p ≤ 0.05): ▲ T0-T1; ■ T0-T2. 
Between-groups significant results (p ≤ 0.05): ★ T1 PT vs T1 CTRL; ✦ T1 CT vs T1 CTRL; ☆ T2 PT vs T2 CTRL; ✧ T2 CT vs 
T2 CTRL 
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DISCUSSION 
 
The aim of this RCT was to evaluate the effects of CT 
and PT on the progression of the cognitive deficits in 
MCI and AD. In agreement with our hypothesis, the 
natural progression of the cognitive symptoms for both 
MCI and AD was mitigated by CT and PT. Specifically, 
our results confirm the hypothesis that both treatments 
are successful in slowing down the usual worsening of 
cognitive symptoms in patients with MCI and AD. 
Also, secondary outcomes suggest that both treatments 
have positive effects on memory and attention abilities 
in patients with MCI. It is important to note that a 
general amelioration of the cardiovascular risk factors 
and exercise capacity were retrieved in both MCI and 
AD after PT. Long term effects of both CT and PT seem 
to persist after the end of the treatments. Although 
between groups differences at T1 and T2 were generally 
not found, results indicate that MCI retain better than 
AD the achieved adaptations, suggesting that the latter 
may better benefit from a constant rather than a periodic 
treatment. Overall the results of this study suggest that 
PT and CT have similar effectiveness in several cog-
nitive domains and can be incorporated among the non-
pharmacological treatments for patients with MCI and 
AD.  
 
Impact of CT and PT on global cognitive 
impairment in patients with MCI 
 
The results of this study indicate that the overall 
cognitive worsening (measured with MMSE) are 
reduced in patients with MCI undergoing CT and PT. 
Indeed, this study demonstrates a significant difference 
for both experimental treatments in comparison to the 
control group (Figure 2, Panel A). Interestingly, these 
positive effects are persistent for both CT and PT 
leading to long-term effects significantly detectable 3 
months after the treatment ended. As expected, and 
previously reported by our group [16] CTRL underwent 
to a significant decline. The rapid decline in cognitive 
functioning is commonly reported in the literature that 
reported a loss of 3 or more points on the MMSE score 
in 6 months. [12, 17]. The effects of cognitive treat-
ments in postponing cognitive decline in persons with 
MCI is also confirmed in a recent meta-analysis that 
showed memory and multidomain-lifestyle intervene-
tions to facilitate partial activation of compensatory 
scaffolding and neuroplasticity [18].  The effectiveness 
of PT were confirmed in reviews and meta-analysis [5, 
12, 14, 19, 20] that showed PT, in particular aerobic 
exercise, to improves global cognitive scores [21-23], 
with a moderate but significant effect on memory [5] 
and executive control processes such as planning, 
scheduling, dealing with ambiguity, working memory 
and multitasking [24].  Overall, our results are highly 
relevant because for the first time the efficacy of a PT 
has been compared with a CT, and the potential 
integration of these successful approaches in the 
standard clinical scenario likely expand the possible 
treatments.  
 
Impact of CT and PT on global cognitive 
impairment in patients with AD 
 
The results of this study indicate that both CT and PT 
preserved the cognitive status in AD during the six 
months of treatment. Unfortunately, both groups but in 
particular CT exhibited a severe drop in the cognitive 
performance 3 months after the training (Figure 2, Panel 
B). This lack of long-term effects is probably due to the 
more severe cognitive and physical impairments of 
these patients, which may require continuous 
treatments. As expected, the global cognitive status of 
the CTRL group progressively worsened. 
 
Our data are in agreement with the positive effect of CT 
on general cognition in AD [15]. Moreover, the positive 
effects of PT in our RCT are in line with several recent 
studies in AD [25-30]. As previously reported by our 
group [28, 31], it is possible to stabilize the progressive 
cognitive dysfunctions in nursing home residents with 
AD through a specific moderate intensity endurance and 
resistance training. These data suggest that the practice 
of regular physical activity might contribute to slower 
cognitive decline. However, ~57% of previous studies 
used the MMSE as the only cognitive outcome measure 
[32], and this may not be sensitive enough to change 
because it does not explore in depth any cognitive 
domain, and in particular the memory deficits 
associated with AD. The use of other cognitive 
outcomes in this study further supports the effectiveness 
of CT and PT. 
 
Impact of CT and PT on specific cognitive domains 
in patients with MCI 
 
In patients with MCI we observed that 6 months of CT 
or PT improved memory compared with CTRL group. 
Furthermore, both CT and PT have an impact on 
selective attention, shifting ability and executive 
functions. 
 
The effects of CT on mental flexibility, memory, 
executive function, processing speed, attention, and 
fluid intelligence was demonstrated in a previous RCT 
[25] and systematic review [33].  
 
Exercise to prevent dementia and delay cognitive 
decline have gained considerable attention in recent 
years [34]. In particular, several studies have 
demonstrated that PT can impact attention [25, 35, 36] 
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and executive functions [27, 35]. However, conflicting 
results are present in the literature on delayed recall [28, 
36].  Nevertheless, previous studies reported relatively 
short duration of PT (6 weeks - 3 months), and the 
compliance was rarely reported. These two variables 
may explain less efficacy of PT on memory in MCI. 
Our data suggest that PT or CT may alter the trajectory 
of specific cognitive domains decline in MCI. These 
results confirm the efficacy of CT and PT on cognitive 
decline in MCI and corroborate the need to add these 
strategies to pharmacological treatment. 
 
Impact of CT and PT on specific cognitive domains 
in patients with AD 
 
CT and PT had an effect on some cognitive domains in 
AD, but in comparison to MCI these effects dropped 
quickly after the end of treatment. The effect of PT on 
attention and global cognition after the treatment is in 
keeping with previous studies [29]. Overall the results 
obtained in AD and MCI converge towards a possible 
overlap of the effects of the two treatments. Indeed, the 
effects of treatments seem to vanish after 3 months of 
inactivity, suggesting the need of a constant training.  
 
Impact of CT and PT on cardiovascular risk factors 
in patients with MCI 
 
In patients with MCI we observed that 6 months of PT 
showed significant ameliorations of BMI, 6MWT, 
systolic and diastolic blood pressure, glucose, 
cholesterol and triglycerides. On the contrary, these 
parameters were not changed after CT and worsened in 
the CTRL group.  
 
Strong evidence supports the notion that cardiovascular 
disease risk factors, such as hypertension, hyper-
cholesterolemia, and glucose intolerance, contribute to 
the onset, development and exacerbation of dementia 
[4, 31, 37] and many studies suggest the opportunity of 
using physical exercise for both, primary and secondary 
AD prevention. 
 
Impact of CT and PT on cardiovascular disease risk 
factors in patients with AD 
 
In patients with AD, the analysis of cardiovascular risk 
factors at T1 revealed significant amelioration in BMI, 
systolic and diastolic blood pressure, glucose and 
triglycerides in PT group. Indeed physical activity is 
known to be the most potent long-term vaso-protective 
non-pharmacological treatment and has a strong impact 
on many of those factors [31, 38, 39], influencing the 
threshold of manifestation of AD by way of 
strengthening vascular plasticity [38]. Moreover, higher 
cardiorespiratory fitness is associated with a diminution 
of Aβ related effects on cognition, suggesting that 
exercise might play an important role in AD [40].  
 
Exercise-induced effects on cardiovascular system 
might be largely explained by a variety of vascular and 
cardiac molecular mechanisms that provide a protective 
environment in cardiovascular system, this beneficial 
effect can be extended to cerebral vasculature as well 
[38]. 
  
However, these cardiovascular risk factors improve-
ments were not maintained 3 months after the end of 
PT, suggesting, the need of a constant training for 
patients with AD. As expected, these cardiovascular 
disease risk factors were not affected by the CT, who 
underwent a worsening of triglycerides. 
 
Responsible pathways underlying the effectiveness of 
the two treatments  
 
The positive cognitive outcome retrieved in this RCT 
are likely induced by different physiological effects 
induced by CT or PT. For instance, it is well established 
that regular exercise lowers the blood pressure and 
lipids, preventing metabolic syndrome and having 
positive effects on inflammatory markers and 
endothelial functions, recognized risk factors for AD. 
Moreover, the current literature demonstrates that six 
months of aerobic training in 70 to 80 year-old 
community-dwelling women with probable MCI, may 
increase hippocampal volume by increasing levels of 
BDNF, which stimulate neurogenesis and increase the 
complexity of the dendritic network. Erickson et al. [64] 
found that one year of aerobic exercise in late adulthood 
is sufficient to enhancing hippocampus volume. This 
volume enhancement translates to improved memory 
function. Therefore, PT may be neuroprotective and 
starting an exercise regimen later in life is not futile for 
either enhancing cognition or augmenting brain volume 
[64]. Moreover, chronic aerobic exercise improves 
regional cerebral blood flow in various relevant brain 
structures, primarily in hippocampus, in response to 
cognitive tasks along with better task performance [41].  
 
On the other side, CT in MCI and AD seems to improve 
cognitive reserve. The current literature reported that 
this resulted in significantly slower decline of brain 
metabolism, especially in left anterior temporal pole and 
anterior cingulate cortex [42].  
 
LIMITATIONS OF THE STUDY 
 
A limitation of the current study was the relatively 
small sample size, which may have influenced the 
differences induced by the training adopted in the 
participants. However, due to the complexity of the 
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study and the limited availability of the participants 
eligible for the present investigation, the sample size 
was small. Further limitations were the mixed gender of 
the sample, and the potential effects of comorbidities. 
Another limitation of the study is the use of the RPE 
during the PT. It is known that the effort perceived by 
demented individuals might be altered by the disease 
itself, thus using RPE scale may give wrong feedback if 
this is used as a unique method to monitor exercise 
intensity. However, we used the RPE scale together 
with the HR monitor during every exercise session to 
understand the state of the participants and to have an 
instantaneous feedback about the effort feeling while 
exercising.  
 
CONCLUSION 
 
This study confirms the positive effect of CT and PT on 
cognitive impairment in MCI and AD. The results 
contribute to the growing body of literature that 
indicates the potentially beneficial relationship between 
physical exercise and cognition, this is the first study 
demonstrating that CT was not superior to PT.  
 
METHODS 
 
Trial design 
 
A single-blind randomized controlled trial (RCT) 
comparing the effects of CT with PT on cognitive 
performance was performed. The examiner was blinded 
to group assignment (allocation ratio 1:1). The study 
was carried out in accordance with the Helsinki 
Declaration and approved by the ethics committee of 
the University Hospital Verona, Italy (Protocol CE 
2389; ClinicalTrials.gov Identifier is NCT03034746). 
The study was reported in accordance with the 
CONSORT guidelines. 
 
Participants 
 
Outpatients with MCI and AD were recruited from the 
Department of Neuroscience, Biomedicine and 
Movement Sciences (University of Verona) and Mons. 
Mazzali Geriatric Institute between January 2014 and 
February 2016. 
 
Inclusion criteria were (a) aged 65-90 years; (b) clinical 
diagnosis of MCI due to AD and probable AD 
dementia, established according to the National Institute 
on Aging-Alzheimer's Association diagnostic guideline 
for MCI due to AD and AD [43, 44], (c) Performance 
Oriented Mobility Assessment-POMA>19) [45]. 
 
Exclusion criteria were: modifications of medications 
during the last 3 months, a history of depression or 
psychosis, alcohol or drug abuse, other neurological, 
cardiac, orthopedic, or respiratory pathology (e.g., 
chronic obstructive pulmonary disease). 
 
After a first evaluation, patients were randomized 
assigned to CT, PT or control group (CTRL). The flow 
chart of the study is reported in Figure 1. 
 
Patients and their relatives were informed about the 
experimental nature of the study and gave their written 
informed consent.  
 
Interventions 
 
Each patient underwent a group treatment 90-
minute/day, three days/week for 72 treatment sessions. 
Each group included 7-8 patients with the same degree 
of cognitive decline. During the study patients were not 
allowed other types of PTs or CTs.  
 
CTRL group received the standard pharmacological 
treatment. PT and CT groups kept previous pharma-
cological treatment. During the study, drug therapies 
were unchanged. 
 
Cognitive treatment 
 
CT, conducted by two neuropsychologists (ratio 2:5), 
was adjusted according to the severity of the cognitive 
decline observed, replicating or adapting two programs 
present in literature [32, 46].  For patients with MCI, 
CT aimed to reduce the impaired skills, acquire 
compensatory strategies using external aids, and use 
ecological materials such as the reconstruction of 
scenarios related to daily life situations. The inter-
vention program has been configured as a cognitive 
rehabilitation and mainly memory rehabilitation: the 
participants were trained in practicing restorative and 
compensatory mnemonic techniques, such as visual 
imagery, face-name association, calendar, notes and 
prompts. In patients with AD, CT was based upon the 
stimulation (and not rehabilitation) of residual cognitive 
skills. Each session began with an introduction of each 
subject to the other members of the group, aiming to 
provide continuity and orientation by beginning all 
sessions in the same way. After that, oral and paper-
pencil exercises of specific cognitive functions were 
proposed. The session also included activation of 
everyday life activities, leisure activities and topics of 
common interest (e.g. music and food), taking into 
account the group’s cognitive capabilities. These 
exercises aimed to the natural process of reminiscence, 
but they also focused on the present situation, having an 
impact on social interaction and mood. Multisensory 
stimulation was introduced.  
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Physical treatment 
 
PT, conducted by two kinesiologists (ratio 2:5), 
included moderate intensity endurance and resistance 
training. Sessions started with 15 minutes of warm-up 
which included active joint mobilization and walking on 
treadmill at preferred speed. Then, patients performed 
45-minute of endurance exercises divided in: 15-minute 
of cycling on cycle ergometer, 15-minute of walking on 
a treadmill, 15-minute of arm cranking on a specific 
ergometer with a random order. The 70% of maximal 
heart rate was calculated using the Karvonen formula 
[47]  (220-age in years) because no specific equation are 
validated in patients with dementia. For participants  
taking beta-blockers the 65% of (220-age) was 
considered, as suggested by Carvalho et al. [48]. Work 
load intensity was increased, if it was possible, by 5% 
every 6 weeks and was monitored by HR monitor belt 
and by the Rating of Perceived Exertion scale (RPE) 
[49]. The RPE scale was not used to set the intensity, 
which was based on HR of the participant during each 
aerobic exercise, but it was used as an extra tool to 
monitor how patients perceived the effort during the 
aerobic training section. Although participants were not 
completely naïf to aerobic exercise, exercising at a 
certain intensity for some minutes was not so easy for 
them, especially at the beginning of the study. The RPE 
scale was useful to monitor the global effort 
experienced by the patients during the training. 
Furthermore, patients started with a low intensity 
aerobic training in the first PT sessions, aiming to reach 
the 70% intensity in 2 weeks. This allowed to set the 
right intensity for all the exercise included in this 
training section, in particular for the arm cracking 
device which may be more challenging than other 
training equipment. All the participants reached the 
required intensity within 2 weeks.  
 
Subsequently, patients performed 3 sets of 12 reps of 
resistance exercises at 85% of 1 repetition maximum 
(1RM), estimated with the Brzicky methods, for 
isotonic ergometers including chest-press, lat-machine, 
leg-press [50]. Selected patients were all naïf to 
resistance training and due to the short familiarization 
(1 day) with exercise devices, the estimate of the one 
repetition maximum was likely underestimated. There-
fore, during the first week of PT we asked the 
participants to perform as many repetitions as possible 
with the 85% of the estimated 1RM. Furthermore, as 
soon as participants were able to perform the 12 
repetitions easily (that means they were able to execute 
more than 12 repetitions) the workload was increased 
by 5%.  
 
PT ended with stretching exercises for all the muscles 
involved in the training. The kinesiologists motivated 
the participants and gave patients time to perform the 
exercise as a whole. 
 
Outcome measures 
 
Primary and secondary outcome measures were 
measured by the same blinded examiners before (T0), 
immediately after treatment (T1), and at three-months 
follow-up (T2). The cognitive assessment was carried 
out in one day, specifically in 2 hours, in the order in 
which they are mentioned above. The physical function 
assessment was carried out the next day. 
 
Primary outcome 
The primary outcome was the Mini Mental State 
Examination (MMSE) to assess the global cognitive 
impairment [51]. Although the MMSE is a screening 
test, it has been used as primary outcome measure in 
studies on AD [52, 53].  
 
Secondary outcomes 
Secondary outcomes for MCI: 
 
Trail Making Test to evaluate the attention ability, in 
particular selective attention, psychomotor speed and 
sequencing skills (TMT-A) and the ability to switch 
attention between two rules or tasks (TMT-B). The time 
taken to complete the trails was recorded [54].  
 
Rivermead Behavioral Memory Test (RBMT), an 
ecological memory battery resembling everyday tasks, 
with the aim to measure daily memory function. The 
RBMT-3 consists of ten subtests (Names, Belongings, 
Appointments, Picture Recognition, Story, Faces, 
Route, Message, Orientation, Novel Task) and has two 
parallel versions for monitoring changes over time [55]. 
  
Secondary outcomes for AD: 
 
Digit Cancellation Test (DCT) to assess visual-selective 
attention. Three matrices are shown to the subject and 
the patients has to cross the target stimuli between 
distractor stimuli [56].  
 
Cognitive section of the Alzheimer’s Disease 
Assessment Scale (ADAS-Cog) to assess the global 
cognitive decline investigating skills in 9 functional 
sub-test (i.e. comprehension, memory and execution of 
orders) and 2 memory sub-tests (words recall and 
recognition) [57].  
 
Secondary outcomes for MCI and AD: 
 
Frontal Assessment Battery (FAB) it is a short cognitive 
and behavioural six-subtest battery that assess executive 
functions (similarities: participants have to identify the 
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link between two objects from the same semantic 
category and it explores conceptualisation; phonological 
verbal fluency: participants have to produce in a minute 
as many words as they can beginning with the letter “S” 
and it explores mental flexibility; motor series: 
participants have to perform Luria’s “fist-edge-palm” 
series six times consecutively and this task explores 
motor programming; conflicting instruction: partici-
pants have to provide an opposite response to 
examiner’s alternating signal and it explores sensitivity 
to interference, go-no go task: it is used the same 
alternating signals of the previous task but here 
participants have to provide different responses and this 
task explores inhibitory control; prehension behaviour: 
the examiner touches both participant’s palms and this 
explores the spontaneous tendency to adhere to the 
environment and environmental autonomy) [59].  
 
Instrumental Activities of Daily Living (IADL) to assess 
the independence of patient in some instrumental 
activities of daily living (i.e. use of the telephone, 
shopping, food preparation) (Range :0-5/8; higher score 
indicates better autonomy) [59]. 
 
Neuropsychiatric Inventory (NPI) to evaluate the 
presence, frequency and severity of behavioral disorders 
[60].  
 
Body mass index (BMI) to measure general body 
composition. Fasted body mass and height were 
measured in the morning with a professional 
mechanical scale fitted with a stadiometer (Seca mod. 
713; III-M; Seca Medical Scales and Measuring 
Systems, Birmingham, UK). BMI was than calculated 
as body mass relative to squared height. 
 
Six-Minute Walking Test (6MWT) to measure the 
maximum distance that a person can walk over 6 min 
and it is commonly used as an assessment of exercise 
capacity. The participants were instructed to walk from 
one end of a 30-meter course to the other and back 
again as many times as possible in 6 min, under the 
supervision of a kinesiologist. After each minute, 
participants were informed of the time elapsed and were 
given standardized encouragement. The distance 
(meters) covered in 6 minutes was recorded [61].  
 
Blood pressure: One skilled physician measured blood 
pressure with standard auscultatory and mercury 
sphygmomanometer technique at about the same time 
of the day to minimize the effect of circadian rhythm 
on the measurement. The standard error of measure-
ment of systolic blood pressure and diastolic blood 
pressure are ± 0.7 (mmHg), and ±1.1 (mmHg), 
respectively [62].  
Blood sample and analysis: Venous peripheral blood 
(25 mL) was collected between 9:00 and 10:00 am in a 
fasted state and processed within 2 hours to obtain 
routine measurements of blood (Glucose, Total 
Cholesterol, High-Density Lipoprotein-HDL, Low-
Density Lipoprotein-LDL, Triglycerides). 
 
Randomization and masking  
 
After screening, participants were allocated to one of 
three arms according to a simple software-generated 
randomization scheme (www.randomization.com): (1) 
CT group, (2) PT group, and (3) CTRL group. The 
research team included “evaluators” and “treatment 
givers”. Evaluators were uninformed about group 
assignments, including physician and neuropsychologist 
who performed outcome measures. Treatment givers 
included neuropsychologists and kinesiologists who 
administered CT and PT, respectively.  
 
Statistical analysis 
 
The sample size has been calculated based on the 
MMSE. Indeed, to obtain a significant effect size of 2 
MMSE points [63], a sample size of 90 participants was 
chosen to guarantee a power of the study of 99% and a 
Type I error of 1%. 
 
Statistical analysis was carried out using the PRISM 
statistical package, version 6 and STATISTICA 
package. 
 
A one-way (1x3) analysis of variance (ANOVA) was 
applied to age, education, MMSE, and POMA between-
groups to test the homogeneity of the groups before the 
study. A three-way (3x3x2) repeated-measure ANOVA 
(rm-ANOVA) was carried out on the primary outcome 
and on secondary outcomes that were explored both in 
MCI and AD, with “Time” as within-group factor, and 
“Treatment” (PT, CT, CTRL) and “Group” (MCI, AD) 
as between-group factors. 
 
A two-way (3x3) rm-ANOVA, with “Time” as within-
group factor, and “Treatment” (PT, CT, CTRL) as 
between-group factors was applied to secondary 
outcome measures tested in MCI and AD groups only.  
 
In the presence of significant effects, a multiple 
comparisons tests with Bonferroni’s correction was 
performed. The familywise alpha level for significance 
was set at 0.05 (two-tails), with Bonferroni’s correction 
when needed, for all the analyses.  
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